Ibezapolstat (ACX-362E)

About Acurx Pharmaceuticals

Acurx Pharmaceuticals is a publicly traded, clinical-stage biotech focused on developing DNA polymerase IIIC inhibitors, a new class of antibiotics for Gram-positive bacterial infections deemed urgent threats. Its primary achievement is advancing its lead candidate, ibezapolstat, into a Phase 2b trial for CDI, with promising early clinical data. The company's strategy is to leverage its focused platform and experienced leadership to achieve regulatory approval for ibezapolstat, potentially under expedited pathways, while exploring the broader utility of its mechanism against other resistant pathogens like MRSA and VRE.

Therapeutic Areas

Other Clostridioides difficile Infection (CDI) Drugs